

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome **GHIA, Paolo, Prospero**
Indirizzo **Via Olgettina 60, 20132, Milano, Italy**
Telefono **02-2643.4797**
Fax **02-2643.2611**
E-mail ghia.paolo@hsr.it

Nazionalità

Data di nascita

ESPERIENZA LAVORATIVA

- Date (da – a) DA GENNAIO 2019
- Nome e indirizzo del datore di lavoro UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- Tipo di azienda o settore UNIVERSITÀ
- Tipo di impiego PROFESSORE DI PRIMA FASCIA, ONCOLOGIA MEDICA
- Principali mansioni e responsabilità DIRETTORE, PROGRAMMA DI RICERCA STRATEGICA SU LEUCEMIA LINFATICA CRONICA
VICE-DIRETTORE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
RESPONSABILE, LABORATORIO DI RICERCA “NEOPLASIE B LINFOCITARIE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
DOCENTE DEI CORSI DI ONCOLOGIA MEDICA NEL CORSO DI LAUREA IN MEDICINA E CHIRURGIA
ATTIVITÀ ASSISTENZIALE DI PAZIENTI AFFETTI DAL LEUCEMIA LINFATICA CRONICA E DISORDINI CORRELATI.
PRINCIPAL INVESTIGATOR/COORDINATORE NAZIONALE IN STUDI CLINICI INTERNAZIONALI DI FASE 1-3
- Date (da – a) DA OTTOBRE 2018 A GENNAIO 2019
- Nome e indirizzo del datore di lavoro UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- Tipo di azienda o settore UNIVERSITÀ
- Tipo di impiego PROFESSORE DI PRIMA FASCIA. MEDICINA INTERNAE
- Principali mansioni e responsabilità DIRETTORE, PROGRAMMA DI RICERCA STRATEGICA SU LEUCEMIA LINFATICA CRONICA
VICE-DIRETTORE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
RESPONSABILE, LABORATORIO DI RICERCA “NEOPLASIE B LINFOCITARIE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
DOCENTE DEI CORSI DI MEDICINA INTERNA E ONCOLOGIA MEDICA NEL CORSO DI LAUREA IN MEDICINA E CHIRURGIA
ATTIVITÀ ASSISTENZIALE DI PAZIENTI AFFETTI DAL LEUCEMIA LINFATICA CRONICA E DISORDINI CORRELATI.
PRINCIPAL INVESTIGATOR/COORDINATORE NAZIONALE IN STUDI CLINICI INTERNAZIONALI DI FASE 1-3

- Date (da – a) Da Gennaio 2016 – Settembre 2018
- Nome e indirizzo del datore di lavoro UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- Tipo di azienda o settore UNIVERSITÀ
- Tipo di impiego Professore di Seconda Fascia, Medicina Interna
- Principali mansioni e responsabilità DIRETTORE, PROGRAMMA DI RICERCA STRATEGICA SU LEUCEMIA LINFATICA CRONICA
VICE-DIRETTORE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
RESPONSABILE, LABORATORIO DI RICERCA “NEOPLASIE B LINFOCITARIE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
DOCENTE DEI CORSI DI MEDICINA INTERNA E ONCOLOGIA MEDICA NEL CORSO DI LAUREA IN MEDICINA E CHIRURGIA
ATTIVITÀ ASSISTENZIALE DI PAZIENTI AFFETTI DAL LEUCEMIA LINFATICA CRONICA E DISORDINI CORRELATI.
PRINCIPAL INVESTIGATOR/COORDINATORE NAZIONALE IN STUDI CLINICI INTERNAZIONALI DI FASE 1-3

- Date (da – a) Da Marzo 2010 – Dicembre 2015
- Nome e indirizzo del datore di lavoro UNIVERSITÀ VITA – SALUTE SAN RAFFAELE, MEDICAL SCHOOL, VIA OLGETTINA 58, 20132, MILANO, ITALIA AND DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, VIA OLGETTINA, 60, 20132 – MILANO, ITALY
- Tipo di azienda o settore UNIVERSITÀ
- Tipo di impiego Professore di Seconda Fascia, Medicina Interna
- Principali mansioni e responsabilità Coordinatore Scientifico della Unità Clinica di Malattie Linfoproliferative, DEPARTIMENTO DI ONCO-EMATOLOGIA, IRCCS OSPEDALE SAN RAFFAELE, MILANO
RESPONSABILE, LABORATORIO DI RICERCA “NEOPLASIE B LINFOCITARIE, DIVISIONE DI ONCOLOGIA SPERIMENTALE, IRCCS OSPEDALE SAN RAFFAELE, MILANO
DOCENTE DEI CORSI DI MEDICINA INTERNA E ONCOLOGIA MEDICA NEL CORSO DI LAUREA IN MEDICINA E CHIRURGIA
ATTIVITÀ ASSISTENZIALE DI PAZIENTI AFFETTI DA MALATTIE LINFOPROLIFERATIVE.
PRINCIPAL INVESTIGATOR/COORDINATORE NAZIONALE IN STUDI CLINICI INTERNAZIONALI DI FASE 1-3 IN LEUCEMIA LINFATICA CRONICA E LINFOMI INDOLENTI.

- Date (da – a) Da Gennaio 2005 ad oggi
- Nome e indirizzo del datore di lavoro Università Vita – Salute San Raffaele, Facoltà di Medicina e Chirurgia, Via Olgettina 58, 20132, Milano, Italia
- Tipo di azienda o settore Università
- Tipo di impiego Ricercatore Universitario confermato in Medicina Interna (MED09)
- Principali mansioni e responsabilità Coordinatore Scientifico della Unità di Malattie Linfoproliferative; attività assistenziale nel campo delle malattie linfoproliferative presso l'Istituto Scientifico San Raffaele, Milano; Responsabile del laboratorio di ricerca di Malattie Linfoproliferative; docente di corsi per studenti universitari di Medicina Interna della facoltà di Medicina e Chirurgia; docente responsabile dei rapporti internazionali e orientamento studentesco della Facoltà di Medicina e Chirurgia

- Date (da – a) Da 1998 al 2004
- Nome e indirizzo del datore di lavoro Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, Via Verdi 15, 10126, Torino, Italia
- Tipo di azienda o settore Università
- Tipo di impiego Ricercatore Universitario in Medicina Interna (MED09)
- Principali mansioni e responsabilità Responsabile di gruppo di ricerca biomedica ed emato-oncologica; docente di corsi per studenti universitari della facoltà di Medicina e Chirurgia; attività assistenziale nel campo ematologico presso l'Ospedale Mauriziano “Umberto I”, Torino

- Date (da – a) Dal 1996 al 1998
- Nome e indirizzo del datore di lavoro Harvard Medical School - Dana Farber Cancer Institute, 44 Binney street, 02115, Boston (MA), USA

- Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Università
 Ricercatore associato (Research Associate)
 Attività di ricerca biomedica ed emato-oncologica; supervisione di studenti di Biologia
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Dal 1994 al 1996
 Istituto di Immunologia di Basilea, 487 Grenzacherstrasse, 4005, Basilea, Svizzera
- Istituto di ricerca privato
 Ricercatore (Scientific Member)
 Attività di ricerca in Immunologia

ISTRUZIONE E FORMAZIONE

- Date (da – a)
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
 - Date (da – a)
- Dal 1998 al 2003
 Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, II Scuola, Polo di Orbassano (TO), Italia
 Scuola di Specialità in Medicina Interna
 Specialista in Medicina Interna
- Dal 1991 al 1994
 Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, Torino, Italia
 Dottorato di Ricerca in Oncologia Umana
 Dottore di Ricerca
- Dal 1984 al 1990
 Università degli Studi di Torino, Facoltà di Medicina e Chirurgia, Torino, Italia
 Corso di Laurea in Medicina e Chirurgia
 Laurea in Medicina e Chirurgia

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

CAPACITÀ E COMPETENZE

ARTISTICHE

Musica, scrittura, disegno ecc.

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

Italiano

Inglese

eccellente

eccellente

eccellente

Elevata capacità a vivere e lavorare con altre persone, in ambienti multiculturali, maturata durante le varie e prolungate esperienze lavorative all'estero, svolgendo una attività di ricerca in vari campi della medicina e delle biotecnologie che presuppone la necessità di comunicare ed interagire continuamente con i propri colleghi.

Elevata capacità a coordinare ed organizzare l'attività di lavoro di persone con elevato preparazione culturale e motivazioni professionali quali studenti universitari, dottorandi, post-doc, borsisti di ricerca e personale tecnico presente nei laboratori di ricerca; elevata capacità amministrativa di fondi di ricerca, includendo selezione del personale lavorativo; elevata capacità nella ideazione e stesura di progetti di ricerca, specialmente indirizzata all'ottenimento di fondi di ricerca da enti erogatori pubblici e privati (ministeri, Fondazioni, etc).

Attività assistenziale di pazienti affetti da Malattie linfoproliferative e Leucemia Linfatica Cronica. Principal Investigator/Coordinatore nazionale in studi nazionali ed internazionali di Fase 1-3 in Leucemia Linfatica Cronica e Linfomi Indolenti. Membro di Advisory Boards Nazionali e Internazionali di ditte farmaceutiche. Gestione ed interpretazione di tecniche innovative di biologia molecolare, in oncologia.

[Non attinenti]

Presidente, European Research Initiative on CLL (ERIC) (dal 2015)

Membro: WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies (dal 2014)

Associate editor (CLL and related disorders) per Hemasphere (2017-oggi)

Associate editor (CLL and related disorders) per Haematologica/The Hematology Journal (2014-2017)

Section Editor (CLL and related disorders) per Leukemia Journal (2008-2013);

Deputy Editor (Lymphoma and CLL) per Blood Cancer Journal (2010-2014);

Attività di referaggio per riviste scientifiche a peer-reviewed: Blood, Clinical Cancer Research, Lancet Oncology, Leukemia,, Haematologica, Leukemia Research, Leukemia & Lymphoma.

Membro dello Steering committee: European Research Initiative on CLL (ERIC), www.ericll.org

Membro dei Comitati Organizzatori e Scientifici per l' "Educational Workshop of Immunoglobulin Genes analysis in Chronic Lymphocytic Leukemia" (2007-2009, annually; 2011-2019 biannually), www.igcll.com

Co-organizer, II and III edition, "Young CLL Investigators Meeting" (London 2007; Cologne 2008)

Membro del Comitato Tecnico-Scientifico della Associazione Italiana per la Ricerca sul Cancro (AIRC) (2008-2013)

Membro: Scientific Program Committee (SPC) (CLL and Lymphoma expert) della European

Per ulteriori informazioni:

www.cedefop.eu.int/transparency

www.europa.eu.int/comm/education/index_it.html

www.eurescv-search.com

Hematology Association (EHA) (2007-2011)
Membro delle Società Scientifiche: American Society of Hematology (ASH), American Association of Immunologists (AAI), European Hematology Association (EHA), American Association for Cancer Research (AACR) Henry Kunkel Society of America, Rockefeller University, New York, Società Italiana di Ematologia Sperimentale (SIES), Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA).”

PATENTE O PATENTI Patente B di guida per autoveicoli: patente nautica

ULTERIORI INFORMAZIONI [Inserire qui ogni altra informazione pertinente, ad esempio persone di riferimento, referenze ecc.]

ALLEGATI ELENCO PUBBLICAZIONI SCIENTIFICHE

Publicazioni scientifiche su riviste internazionali sottoposte a referaggio (dal 2014)

1. Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, **Ghia P**, Papakonstantinou N, Stamatopoulos K. *Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia*. Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262. No abstract available. PMID: 31227476
2. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, **Ghia P**, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. *Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies*. Blood Adv. 2019 Jun 25;3(12):1799-1807. Doi 10.1182/bloodadvances.2018028761. PMID: 31196847
3. Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, **Ghia P**, Foà R, Caligaris-Cappio F, Gobbi M. *Olaptosed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia*. Haematologica. 2019 May 16. pii: haematol.2018.205930. doi: 10.3324/haematol.2018.205930. PMID: 31097627
4. Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, **Ghia P**, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. *IGF1R as druggable target mediating PI3K- δ inhibitor resistance in a murine model of chronic lymphocytic leukemia*. Blood. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029. [Epub ahead of print] PMID: 31010847
5. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, **Ghia P**, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. *Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia*. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17. PMID: 30995176
6. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, **Ghia P**, Chang S, Ninomoto J, James DF, Burger JA. *Outcomes with ibrutinib by line of therapy and post-*

ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 Feb 14. doi: 10.1002/ajh.25436. [Epub ahead of print] PMID: 30767298

7. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. *Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.* Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15791. [Epub ahead of print] No abstract available. PMID: 30740654

8. Moysiadis T, Baliakas P, Rossi D, Catherwood M, Strefford JC, Delgado J, Anagnostopoulos A, Belessi C, Stavroyianni N, Pospisilova S, Oscier D, Gaidano G, Campo E, Rosenquist R, **Ghia P**, Stamatopoulos K. *Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors.* Leukemia. 2019 Jan 24. doi: 10.1038/s41375-018-0322-7. PMID: 30679797

9. Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, **Ghia P**. *Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.* Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0335-2. PMID: 30607020

10. Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, NguyenKhac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksa AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, **Ghia P**, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K. *Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact.* Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan PMID: 30602617

11. Ten Hacken E, Gounari M, **Ghia P**, Burger JA. *The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.* Leukemia. 2019 Feb;33(2):287-298. doi: 10.1038/s41375-018-0303-x. Epub 2018 Dec 16. PMID: 30555163

12. Agathangelidis A, Sutton LA, Hadzidimitriou A, Tresoldi C, Langerak AW, Belessi C, Davi F, Rosenquist R, Stamatopoulos K, **Ghia P**. *Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation.* J Vis Exp. 2018 Nov 26;(141). doi: 10.3791/57787. PMID: 30531723

13. Brown JR, Moslehi J, Ewer MS, O'Brien SM, **Ghia P**, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. *Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.* Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2. PMID: 30506764

14. Xochelli A, Bikos V, Polychronidou E, Galigalidou C, Agathangelidis A, Charlotte F, Moschonas P, Davis Z, Colombo M, Roumelioti M, Sutton LA, Groenen P, van den Brand M, Boudjoghra M, Algara P, Traverse-Glehen A, Ferrer A, Stalika E, Karypidou M, Kanellis G, Kalpadakis C, Mollejo M, Pangalis G, Vlamos P, Amini RM, Pospisilova S, Gonzalez D,

Ponzoni M, Anagnostopoulos A, Giudicelli V, Lefranc MP, Espinet B, Panagiotidis P, Piris MA, Du MQ, Rosenquist R, Papadaki T, Belessi C, Ferrarini M, Oscier D, Tzouvaras D, **Ghia P**, Davi F, Hadzidimitriou A, Stamatopoulos K. *Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations*. J Pathol. 2019 Apr;247(4):416-421. doi: 10.1002/path.5209. Epub 2019 Jan 30. PMID: 30484876

15. Polychronidou E, Kalamaras I, Agathangelidis A, Sutton LA, Yan XJ, Bikos V, Vardi A, Mochament K, Chiorazzi N, Belessi C, Rosenquist R, **Ghia P**, Stamatopoulos K, Vlamos P, Chailyan A, Overby N, Marcatili P, Hatzidimitriou A, Tzouvaras D. *Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia*. BMC Bioinformatics. 2018 Nov 20;19(Suppl 14):414. doi: 10.1186/s12859-018-2381-1. PMID: 30453883 Free PMC Article

16. Papakonstantinou N, Ntoufa S, Tsagiopoulou M, Moysiadis T, Bhoi S, Malousi A, Psomopoulos F, Mansouri L, Laidou S, Papazoglou D, Gounari M, Pasentsis K, Plevova K, Kuci-Emruli V, Duran-Ferrer M, Davis Z, Ek S, Rossi D, Gaidano G, Ritgen M, Oscier D, Stavroyianni N, Pospisilova S, Davi F, **Ghia P**, Hadzidimitriou A, Belessi C, Martin-Subero JJ, Pott C, Rosenquist R, Stamatopoulos K. *Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia*. Int J Cancer. 2018 Nov 16. doi: 10.1002/ijc.31999. [Epub ahead of print] PMID: 30447004

17. Campo E, Cymbalista F, **Ghia P**, Jäger U, Pospisilova S, Rosenquist R, Schuh A, Stilgenbauer S. *TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics*. Haematologica. 2018 Nov 15. pii: haematol.2018.187583. doi: 10.3324/haematol.2018.187583. [Epub ahead of print] PMID: 30442727

18. **Ghia P**. *From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development*. Front Immunol. 2018 Oct 24;9:2402. doi: 10.3389/fimmu.2018.02402. eCollection 2018. No abstract available. PMID: 30410485

19. Agathangelidis A, Rosenquist R, Davi F, **Ghia P**, Belessi C, Hadzidimitriou A, Stamatopoulos K. *Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia*. Methods Mol Biol. 2019;1881:51-62. doi: 10.1007/978-1-4939-8876-1_5. PMID: 30350197

20. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, **Ghia P**, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. *The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL*. Blood. 2018 Oct 4. pii: blood-2018-05-850461. doi: 10.1182/blood-2018-05-850461. [Epub ahead of print] PMID: 30287523

21. Angelillo P, Capasso A, **Ghia P**, Scarfò L. *Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach?* Eur J Intern Med. 2018 Sep 26. pii: S0953-6205(18)30367-4. doi: 10.1016/j.ejim.2018.09.006. [Epub ahead of print] Review. PMID: 30268574

22. Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford

JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, **Ghia P**, Rosenquist R, Stamatopoulos K. *Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia*. *Haematologica*. 2018 Sep 27. pii: haematol.2018.195032. doi: 10.3324/haematol.2018.195032.

23. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galienucci P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, **Ghia P**.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Haematologica. 2018 Apr 19. pii: haematol.2018.189837. doi: 10.3324/haematol.2018.189837. [Epub ahead of print] PMID: 29674504

24. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, **Ghia PP**, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL *Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding*.

Hematol Oncol. 2018 Mar 7. doi: 10.1002/hon.2503. [Epub ahead of print] Review. PMID: 29512173

25. Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, **Ghia P**, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. *ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation*. *Leukemia*. 2018 Feb 2. doi: 10.1038/s41375-017-0007-7. [Epub ahead of print] Review. PMID: 29467486

26. Agathangelidis A, Ljungström V, Scarfò L, Fazi C, Gounari M, Pandzic T, Sutton LA, Stamatopoulos K, Tonon G, Rosenquist R, **Ghia P**. *Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations*. *Haematologica*. 2018 Feb 15. pii: haematol.2017.177212. doi: 10.3324/haematol.2017.177212. [Epub ahead of print] PMID: 29449433 Free Article

27. Gribben JG, Bosch F, Cymbalista F, Geisler CH, **Ghia P**, Hillmen P, Moreno C, Stilgenbauer S.

Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

Br J Haematol. 2018 Jan 9. doi: 10.1111/bjh.15080. [Epub ahead of print] PMID: 29318593

28. Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, **Ghia P**, Rosenquist R, Stamatopoulos K. *No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy*.

Haematologica. 2017 Dec 21. pii: haematol.2017.182634. doi: 10.3324/haematol.2017.182634. [Epub ahead of print] No abstract available. PMID: 29269523

29. Pal K, Bystry V, Reigl T, Demko M, Krejci A, Touloumenidou T, Stalika E, Tichy B, **Ghia P**, Stamatopoulos K, Pospisilova S, Malcikova J, Darzentas N. *GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data*. *Bioinformatics*. 2017 Dec 1;33(23):3802-3804. doi: 10.1093/bioinformatics/btx423.
30. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, **Ghia P**, Montserrat E. *Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project*. *Cytometry B Clin Cytom*. 2017 Oct 10. doi: 10.1002/cyto.b.21595. [Epub ahead of print]
31. Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, **Ghia P**, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. *Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study*. *Lancet Haematol*. 2017 Sep 12. pii: S2352-3026(17)30171-0. doi: 10.1016/S2352-3026(17)30171-0
32. Jiménez de Oya N, De Giovanni M, Fioravanti J, Übelhart R, Di Lucia P, Fiocchi A, Iacovelli S, Efremov DG, Caligaris-Cappio F, Jumaa H, **Ghia P**, Guidotti LG, Iannacone M. *Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens*. *EMBO Mol Med*. 2017 Sep 12. pii: e201707732. doi: 10.15252/emmm.201707732.
33. Fonte E, Vilia MG, Reverberi D, Sana I, Scarfò L, Ranghetti P, Orfanelli U, Cenci S, Cutrona G, **Ghia P**, Muzio M. *TLR9 stimulation can induce IkappaBzeta expression and IgM secretion in chronic lymphocytic leukemia cells*. *Haematologica*. 2017 Aug 3. pii: haematol.2017.165878. doi: 10.3324/haematol.2017.165878.
34. Ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfo L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, **Ghia P**, Burger JA. *Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia*. *Haematologica*. 2017 Jul 27. pii: haematol.2017.169102. doi: 10.3324/haematol.2017.169102.
35. Brown JR, Moslehi J, O' Brien S, **Ghia P**, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. *Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials*. *Haematologica*. 2017 Jul 27. pii: haematol.2017.171041. doi: 10.3324/haematol.2017.171041.

36. Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, **Ghia P***, Degano M. *Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia*. *Corresponding author and co-senior author
Nat Commun. 2017 Jun 9;8:15746. doi: 10.1038/ncomms15746.
37. Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, **Ghia P**, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). *Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification*.
Haematologica. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605
38. Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. *Chronic lymphocytic leukemia with mutated IGHV4/34 receptors: shared and distinct immunogenetic features and clinical outcomes*.
Clin Cancer Res. 2017 May 23. pii: clincanres.3100.2016. doi: 10.1158/1078-0432.CCR-16-3100.
39. Bernardi R, **Ghia P**. Reactivating nuclear PTEN to treat CLL.
Oncotarget. 2017 May 1. doi: 10.18632/oncotarget.17543
40. Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, **Ghia P**, Bellone M, Dellabona P, Casorati G, de Lalla C. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
41. Pouliou E, Xochelli A, Kanellis G, Stalika E, Sutton LA, Navarro A, Agathangelidis A, Dimosthenous K, Anagnostopoulos A, Patsouris E, Korkolopoulou P, Sundstrom C, **Ghia P**, Ponzoni M, Sander B, Campo E, Rosenquist R, Hadzidimitriou A, Stamatopoulos K, Papadaki T. Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence.
Am J Pathol. 2017 Apr 27. pii: S0002-9440(17)30012-3. doi: 10.1016/j.ajpath.2017.02.017.
42. Rosenquist R, **Ghia P***, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, Darzentas N, Giudicelli V, Lefranc MP, Langerak AW, Belessi C, Davi F, Stamatopoulos K. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. *Corresponding author
Leukemia. 2017 May 12. doi: 10.1038/leu.2017.125. [Epub ahead of print] No abstract available.
43. **Ghia P**, Nadel B, Sander B, Stamatopoulos K, Stevenson FK. Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment.
J Intern Med. 2017 Apr 10. doi: 10.1111/joim.12608
44. Vilia MG, Fonte E, Veliz Rodriguez T, Tocchetti M, Ranghetti P, Scarfò L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, **Ghia P**, Muzio M. The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia.
Leuk Lymphoma. 2017 Feb 28;1-7. doi: 10.1080/10428194.2017.1295142
45. Wu SJ, Lin CT, Agathangelidis A, Lin LI, Kuo YY, Tien HF, **Ghia P**. Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.
Haematologica. 2017 Mar 2. pii: haematol.2016.157552. doi: 10.3324/haematol.2016.157552

46. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, **Ghia P**, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol.* 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.
47. **Ghia P**, Scarfò L, Perez S, Pathiraja K, Derosier M, Small K, McCrary Sisk C, Patton N. Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. *Blood.* 2017 Mar 30;129(13):1876-1878
48. McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Shad Thaxton C, **Ghia P**. Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. *Oncotarget.* 2017 Jan 4. doi: 10.18632/oncotarget.14494. [Epub ahead of print]
49. **Ghia P**, Cuneo A. Ibrutinib in the real world patient: many lights and some shades. *Haematologica.* 2016 Dec;101(12):1448-1450. PMID: 27903711
50. Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacomelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, **Ghia P**, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. *Leukemia.* 2016 Nov 28. doi: 10.1038/leu.2016.359. PMID: 27890934
51. Stamatopoulos K, Agathangelidis A, Rosenquist R, **Ghia P**. Antigen receptor stereotypy in chronic lymphocytic leukemia. *Leukemia.* 2016 Nov 4. doi: 10.1038/leu.2016.322. PMID: 27811850
52. Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, **Ghia P**, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. PMID: 27660167
53. Eichhorst B, Robak T, Montserrat E, **Ghia P**, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (<http://www.esmo.org/Guidelines/Haematological-Malignancies>). *Ann Oncol.* 2016 Sep;27(suppl 5):v143-v144. PMID: 27664254
54. **Ghia P**. Ibrutinib holds promise for patients with 17p deletion CLL. *Lancet Oncol.* 2016 Oct;17(10):1342-1343. doi: 10.1016/S1470-2045(16)30442-9. PMID: 27637986
55. Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, **Ghia P**, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP). Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. *Haematologica.* 2016 Sep;101(9):1002-9. doi: 10.3324/haematol.2015.134510. PMID: 27582569
56. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, **Ghia P**, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. *J Immunol.* 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. PMID: 27534555
57. Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, **Ghia P**, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M. ATM mutations in

major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Haematologica. 2016 Sep;101(9):e369-73. doi: 10.3324/haematol.2016.142968. PMID: 27479817

58. Wu SJ, Lin CT, Lin SC, Hsieh PY, Hsu CA, Chu FY, Fazi C, Ghia P, Chuang SS. Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan.

Ann Hematol. 2016 Oct;95(10):1727-9. doi: 10.1007/s00277-016-2747-2. PMID: 27431581

59. Ntoufa S, Vilia MG, Stamatopoulos K, **Ghia P**, Muzio M. Toll-like receptors signaling: A complex network for NF- κ B activation in B-cell lymphoid malignancies.

Semin Cancer Biol. 2016 Aug; 39:15-25. doi: 10.1016/j.semcancer.2016.07.001. PMID: 27402288

60. Scarfò L, Ferreri AJ, **Ghia P**. Chronic lymphocytic leukaemia.

Crit Rev Oncol Hematol. 2016 Aug; 104:169-82. doi: 10.1016/j.critrevonc.2016.06.003. PMID: 27370174

61. Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, **Ghia P**, Corti A. Inhibition of chronic lymphocytic leukemia progression by fulllength chromogranin A and its N-terminal fragment in mouse models.

Oncotarget. 2016 May 17. doi: 10.18632/oncotarget.9407. [Epub ahead of print]

I.F.

5.008

62. Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfo' L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Utoft Niemann C, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, **Ghia P**, Stamatopoulos K, Rosenquist R. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Haematologica. 2016 May 19. pii: haematol.2016.141812. [Epub ahead of print]

I.F 6.671

63. Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A, Giassafaki L, Karamanli T, Bele P, Moysiadis T, Baliakas P, Sutton LA, Stavroyianni N, Anagnostopoulos A, Makris AM, **Ghia P**, Rosenquist R, Stamatopoulos K. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.

Oncotarget. 2016 May 14. doi: 10.18632/oncotarget.9371. [Epub ahead of print]

I.F.

5.008

64. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, **Ghia P**, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Haematologica. 2016 May;101(5):531-40

I.F 6.671

65. Ntoufa S, Papakonstantinou N, Apollonio B, Gounari M, Galigalidou C, Fonte E, Anagnostopoulos A, Belessi C, Muzio M, **Ghia P***, Stamatopoulos K*. B Cell Anergy Modulated by TLR1/2 and the miR-17~92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4. *Co-senior author

J Immunol. 2016 May 15;196(10):4410-7

I.F. 4.985

66. Scarfò L, **Ghia P**. What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges.

Semin Oncol. 2016 Apr;43(2):201-8

I.F. 3.954

67. **Ghia P**. A new life for rituximab?

Lancet Haematol. 2016 Mar;3(3):e103-4

I.F. 4.889

68. Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, **Ghia P**; European Research Initiative on CLL (ERIC). Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Haematologica. 2016 Mar;101(3):263-5

I.F 6.671

69. Galletti G, Scielzo C, Barboglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, **Ghia P**, De Palma M, Caligaris-Cappio F, Bertilaccio MT. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

70. Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, **Ghia P**, Tonon G, Ponzoni M, Caligaris-Cappio F, Bernardi R. HIF-1 α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. *Blood*. 2016 Apr 21;127(16):1987-97 I.F. 11.841
71. **Ghia P**. Targeting Hedgehog in haematological malignancies. *Lancet Haematol*. 2015 Aug;2(8):e311-2. doi: 10.1016/S2352-3026(15)00112-X.
72. Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Clifford R, Sutton LA, Blakemore S, Stavroyianni N, Agathangelidis A, Rossi D, Höglund M, Kotaskova J, Juliusson G, Belessi C, Chiorazzi N, Panagiotidis P, Langerak AW, Smedby KE, Oscier D, Gaidano G, Schuh A, Davi F, Pott C, Strefford JC, Trentin L, Pospisilova S, **Ghia P**, Stamatopoulos K, Sjöblom T, Rosenquist R. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. *Blood*. 2015 Dec 16. pii: blood-2015-10-674572. [Epub ahead of print] I.F. 10.452
73. Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton LA, Papadopoulos G, Agathangelidis A, Papadopoulou E, Davis Z, Algara P, Kanellis G, Traverse-Glehen A, Mollejo M, Anagnostopoulos A, Ponzoni M, Gonzalez D, Pospisilova S, Matutes E, Piris MA, Papadaki T, **Ghia P**, Rosenquist R, Oscier D, Darzentas N, Tzovaras D, Belessi C, Hadzidimitriou A, Stamatopoulos K. AN IMMUNOGENETIC SIGNATURE OF ONGOING ANTIGEN INTERACTIONS IN SPLENIC MARGINAL ZONE LYMPHOMA EXPRESSING IGHV1-2*04 RECEPTORS. *Clin Cancer Res*. 2015 Dec 8. pii: clincanres.1170.2015. [Epub ahead of print] I.F. 8.722
74. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, **Ghia P**, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivoy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med*. 2015 Dec 7. [Epub ahead of print] I.F. 55.873
75. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, **Ghia P**. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study. *Leukemia*. 2015 Dec 7. doi: 10.1038/leu.2015.313. [Epub ahead of print] I.F. 10.431
76. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, **Ghia P**, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *N Engl J Med*. 2015 Dec 17;373(25):2425-37 I.F. 55.873
77. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, **Ghia P**, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood*. 2015 Oct 20. pii: blood-2015-06-65112
78. Vardi A, Agathangelidis A, Stalika E, Karypidou M, Siorenta A, Anagnostopoulos A, Rosenquist R, Hadzidimitriou A, **Ghia P**, Sutton LA, Stamatopoulos K. Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia. *Clin Cancer Res*. 2015 Sep 2. pii: clincanres.3017.2014. [Epub ahead of print]
79. Eichhorst B, Robak T, Montserrat E, **Ghia P**, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v78-v84. doi: 10.1093/annonc/mdv303.

80. Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, **Ghia P***, Stamatopoulos K, Muzio M. Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. ***Corresponding author**
Haematologica. 2015 Aug 20; pii: haematol.2014.119933. [Epub ahead of print]
81. Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton LA, Kminkova J, Scarfo L, Pospisilova S, Gaidano G, Stamatopoulos K, **Ghia P***, Rosenquist R. Prognostic relevance of MYD88 mutations in CLL: the jury is still out. ***Corresponding author and co-senior author**
Blood 2015 Aug 20;126(8):1043-4. doi: 10.1182/blood-2015-05-648634.
82. Agathangelidis A, Scarfò L, Barboglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, **Ghia P**, Caligaris-Cappio F, Scielzo C. Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.
PLoS One. 2015 Jun 25;10(6):e0130195 . doi: 10.1371/journal.pone.0130195. eCollection 2015. I.F. 3.534
83. Mansouri L, Sutton LA, Ljungström V, Bondza S, Arngården L, Bhoi S, Larsson J, Cortese D, Kalushkova A, Plevova K, Young E, Gunnarsson R, Falk-Sörqvist E, Lönn P, Muggen AF, Yan XJ, Sander B, Enblad G, Smedby KE, Juliussen G, Belessi C, Rung J, Chiorazzi N, Strefford JC, Langerak AW, Pospisilova S, Davi F, Hellström M, Jernberg-Wiklund H, **Ghia P**, Söderberg O, Stamatopoulos K, Nilsson M, Rosenquist R. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
J Exp Med. 2015 Jun 1;212(6):833-43 I.F. 13.912
84. Gounari M, Ntoufa S, Apollonio B, Papakonstantinou N, Ponzoni M, Chu CC, Rossi D, Gaidano G, Chiorazzi N, Stamatopoulos K, **Ghia P**. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset 8.
Blood. 2015 Apr 21. pii: blood-2014-09-603217 I.F. 9.775
85. Xochelli A, Sutton LA, Agathangelidis A, Stalika E, Karypidou M, Marantidou F, Lopez AN, Papadopoulos G, Supikova J, Groenen P, Boudjogra M, Sundstrom C, Ponzoni M, Francova HS, Anagnostopoulos A, Pospisilova S, Papadaki T, Tzovaras D, Ghia P, Pott C, Davi F, Campo E, Rosenquist R, Hadzidimitriou A, Belessi C, Stamatopoulos K. Antigen Drive in the Natural History of Mantle Cell Lymphoma: Molecular Evidence.
Am J Pathol. 2015 Apr 2. pii: S0002-9440(15)00138-8. doi: 10.1016/j.ajpath.2015.02.006. [Epub ahead of print] I.F. 4.602
86. Lanasa MC, Andritsos L, Brown JR, Gabilove J, Caligaris-Cappio F, **Ghia P**, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Leuk Res. 2015 Feb 7. pii: S0145-2126(15)00033-8. doi: 10.1016/j.leukres.2015.02.001. [Epub ahead of print] I.F. 2.692
87. Lualdi M, Pedrini E, Rea K, Monti L, Scaldaferrì D, Gariboldi M, Camporeale A, **Ghia P**, Monti E, Tomassetti A, Acquati F, Taramelli R. Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase.
Oncotarget. 2015 Mar 8. [Epub ahead of print] I.F. 6.627
88. Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker AE, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, Gonzalez de Castro D, Dearden C, Pratt G, Ashton-Key M, Rosenquist R, Forconi F, Collins A, **Ghia P**, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford J. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
Clin Cancer Res. 2015 Mar 16. pii: clincanres.2759.2014. I.F. 8.193
89. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliussen G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, **Ghia P***, Rosenquist R, Stamatopoulos K. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. ***Co-senior author**
Blood. 2015 Jan 29;125(5):856-9 I.F. 9.775
90. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obřtlíková P, Laurenti L, Stilgenbauer S, Smolej L, **Ghia P**, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in

- poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Haematologica. 2015 Apr;100(4):511-6 I.F. 5.868
91. Sutton LA, Ljungström V, Mansouri L, Young E, Cortese D, Navrkalova V, Malcikova J, Muggen AF, Trbusek M, Panagiotidis P, Davi F, Belessi C, Langerak AW, **Ghia P**, Pospisilova S, Stamatopoulos K, Rosenquist R. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Haematologica. 2015 Mar;100(3):370-6. doi: 10.3324/haematol.2014.109777 I.F. 5.868
92. Xochelli A, Agathangelidis A, Kavakiotis I, Minga E, Sutton LA, Baliakas P, Chouvarda I, Giudicelli V, Vlahavas I, Maglaveras N, Bonello L, Trentin L, Tedeschi A, Panagiotidis P, Geisler C, Langerak AW, Pospisilova S, Jelinek DF, Oscier D, Chiorazzi N, Darzentas N, Davi F, **Ghia P**, Rosenquist R, Hadzidimitriou A, Belessi C, Lefranc MP, Stamatopoulos K. *Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia*.
Immunogenetics. 2014 Nov 12. [Epub ahead of print] I.F. 2.894
93. Baliakas P, Hadzidimitriou A, Sutton L-A, Minga E, Agathangelidis A, Nichelatti M, Tsanousa A, Scarfò L, Davis Z, Yan X-J, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, van Lom K, Giudicelli V, Skuhrova H, Francova, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc M-P, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Rosenquist R, **Ghia P***, Stamatopoulos K*. *Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study*. *Co-last author and corresponding author
Lancet Haematology, 2014; 1: e74–84
94. Apollonio B, Bertilaccio MT, Restuccia U, Ranghetti P, Barbaglio F, **Ghia P**, Caligaris-Cappio F, Scielzo C. *From a 2DE-Gel Spot to Protein Function: Lesson Learned From HSI in Chronic Lymphocytic Leukemia*.
J Vis Exp. 2014 Oct 19;(92). doi: 10.3791/51942.
95. **Ghia P**. Ibrutinib: better combined with other drugs?
Lancet Oncol. 2014 Sep;15(10):1043-4 I.F. 24.725
96. Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nüchel H, Merkel O, **Ghia P**, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170 I.F. 5.935
97. Vardi A, Agathangelidis A, Sutton LA, **Ghia P**, Rosenquist R, Stamatopoulos K. Immunogenetic Studies of Chronic Lymphocytic Leukemia: Revelations and Speculations about Ontogeny and Clinical Evolution.
Cancer Res. 2014 Aug 15;74(16):4211-4216 I.F. 8.650
98. Simonetti G, Bertilaccio MT, **Ghia P**, Klein U. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.
Blood. 2014 Aug 14;124(7):1010-9 I.F. 9.775
99. Montillo M, Tedeschi A, Gaidano G, Coscia M, Belsito Petrizzi V, Orlandi E, Cascavilla N, **Ghia P**, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M. Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Haematologica. 2014 Jun 27. pii: haematol.2014.106740 I.F. 5.935
100. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, **Ghia P**, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Leukemia. 2014 Jun 19. doi: 10.1038/leu.2014.196 I.F. 10.164
101. **Ghia P***, Hallek M. Management of chronic lymphocytic leukemia.
Haematologica. 2014 Jun;99(6):965-972. *Corresponding author I.F. 5.935

102. Simonetti G, Bertilaccio MT, Veliz Rodriguez T, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, **Ghia P**. SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders. *Haematologica*. 2014 May 23 I.F. 5.935
103. Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, Scarfò L, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, **Ghia P**, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K. *The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors*. *Br J Haematol*. 2014 Apr 12. doi: 10.1111/bjh.12893. [Epub ahead of print]
104. Chatzouli M, Ntoufa S, Papakonstantinou N, Chartomatsidou E, Anagnostopoulos A, Kollia P, **Ghia P***, Muzio M, Stamatopoulos K, Belessi C. *Heterogeneous Functional Effects of Concomitant B Cell Receptor and TLR Stimulation in Chronic Lymphocytic Leukemia with Mutated Versus Unmutated Ig Genes*. ***Corresponding author** *J Immunol*. 2014 May 15;192(10):4518-24
105. Ponzoni M, **Ghia P**. *Clonal B-cell lymphocytosis: a new member?* *Blood*. 2014 Feb 20;123(8):1118-9. doi: 10.1182/blood-2013-12-543330. I.F. 9.775
106. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, **Ghia P**, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. *Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia*. *N Engl J Med*. 2014 Mar 13;370(11):997-1007 I.F. 51.658
107. Rosenquist R, Davi F, **Ghia P**. *The microenvironment in lymphomas - Dissecting the complex crosstalk between tumor cells and 'by-stander' cells*. *Semin Cancer Biol*. 2013 Dec 21. [Epub ahead of print] I.F. 7.436
108. Shim YK, Rachel JM, **Ghia P**, Boren J, Abbasi F, Dagklis A, Venable G, Kang J, Degheidy H, Plapp FV, Vogt RF, Menitove JE, Marti GE. *Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding*. *Blood*. 2013 Feb 27;123(9):1319-26 I.F. 9.775
109. Vardi A, Agathangelidis A, Sutton LA, Chatzouli M, Scarfo L, Mansouri L, Douka V, Anagnostopoulos A, Darzentas N, Rosenquist R, **Ghia P**, Belessi C, Stamatopoulos K. *IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications*. *Clin Cancer Res*. 2014;20:323-330 doi: 10.1158/1078-0432 I.F. 7.837
110. Scarfò L, **Ghia P**. *Reprogramming cell death: bcl2 family inhibition in hematological malignancies*. *Immunol Lett*. 2013;155:36-39 I.F. 2.337
111. Karube K, Scarfò L, Campo E, **Ghia P**. *Monoclonal B cell lymphocytosis and "in situ" lymphoma*. *Semin Cancer Biol*. 2013 Feb;24:3-14 I.F. 7.436
112. Sutton LA, Agathangelidis A, Belessi C, Darzentas N, Davi F, **Ghia P**, Rosenquist R, Stamatopoulos K. *Antigen selection in B-cell lymphomas-Tracing the evidence*. *Semin Cancer Biol*. 2013;23:399-409 I.F. 7.436
113. Martins LR, Lúcio P, Melão A, Antunes I, Cardoso BA, Stansfield R, Bertilaccio MT, **Ghia P**, Drygin D, Silva MG, Barata JT. *Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia*. *Leukemia*. 2014;28:179-182 I.F. 10.164

Autorizzo il trattamento dei miei dati personali ai sensi del Regolamento (UE) 2016/679 sulla Protezione dei Dati Personali (GDPR) e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Milano, 03 Settembre 2019

Paolo Ghia